Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 3/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065276 | 0.83 | PRCP (0.59) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL30167262 | 0.83 | PRCP (0.59) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL14304629 | 0.82 | PRCP (0.39) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL1167895 | 0.79 | PRCP (0.42) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL3111967 | 0.77 | PRCP (0.43) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL9114293 | 0.77 | PRCP (0.36) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL9114302 | 0.77 | PRCP (0.36) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL27896744 | 0.76 | PRCP (0.40) | ALDH1A1KDM4EPRCPSLC22A1MAPT | |
| SCHEMBL13662985 | 0.76 | CYP2D6 (0.38) | ALDH1A1KDM4EPRCPMAPTMAPK1 | |
| SCHEMBL24639493 | 0.76 | PRCP (0.42) | ALDH1A1KDM4EPRCPSLC22A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | claimed |
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-110156660-A | A kind of isoindoline analog derivative and preparation method thereof | 广东工业大学 | 2019-08-23 | — | — | CN | disclosed |
| US-9120818-B2 | Process and intermediates for preparing macrolactams | MERCK SHARP & DOHME CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2651884-A2 | PROCESS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | Merck Sharp & Dohme Corp. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274463-A1 | PROCESS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | MERCK SHARP & DOHME CORP. | 2013-10-17 | — | — | US | disclosed |
| WO-2012082672-A2 | PROCESS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | MERCK SHARP & DOHME CORP. (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-1706466-A2 | COATING COMPOSITIONS, THEIR PREPARATION, AND COATED ARTICLES MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005118731-A2 | COATING COMPOSITIONS, THEIR PREPARATION, AND COATED ARTICLES MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274463-A1 | PROCESS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | EMG1, MRPS18B, MLN | HTR1A 2608/4885ALDH1A1 3301/4885KDM4E 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.